Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2026
Clinical validation of a new multi-Aspergillus species reverse transcriptase quantitative PCR: a diagnostic case-control study.
СтатьяВалидационное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Benazra Marion, Mallek Wicem, Ghelfenstein-Ferreira Théo, Sturny-Leclère Aude, Dellière Sarah, Hamane Samia, Lortholary Olivier, Lanternier Fanny, Alanio Alexandre, OPTIFIL working group, Robin C, Suarez F, Gallego-Hernanz P, Lara D, Thiebaut A, Rohrlich P Simon, Risso K, Gruson B, Morel V, Huynh A, Botterel F, Cateau E, Letscher-Bru V, Pelloux H, Fekkar A, Cassaing S, Chouaki T, Debourgogne A, Bougnoux M E
Аннотация
OBJECTIVES: Invasive aspergillosis is a difficult-to-diagnose fungal disease, the diagnosis of which relies on many criteria including mycological criteria. Recently, the European Organisation for Research and Treatment of Cancer/Mycoses Study Group Education and Research Consortium promoted Aspergillus PCR as a specific marker given the significant progress made in optimizing and standardizing Aspergillus real-time quantitative PCR (qPCR) assays. However, there is no unique and optimal assay in the literature, particularly for optimally detecting aspergillosis due to the main Aspergillus species responsible for invasive aspergillosis.
METHODS: We therefore designed, optimized, and validated a new type of real-time PCR assay using a diagnostic case-control study approach. This assay is based on reverse transcriptase qPCR methodology and multi-Aspergillus section-specific primers (multi Aspergillus species reverse transcriptase qPCR [MAS-RTqPCR]). This assay detects whole nucleic acids from species belonging to six Aspergillus sections (Fumigati, Flavi, Nigri, Terrei, Nidulantes, and Usti).
RESULTS: The limit of detection of this assay was five copies per reaction, and the analytical specificity was 100% based on the screening of >90 fungal species. We used three groups of patients to validate the assay, testing 120 patients and 223 plasma samples. The clinical sensitivity was 0.91 (95% CI, 0.71-0.98) and clinical specificity was 1.00 (95% CI, 0.93-1.00). Follow-up of positive patients revealed superiority of the MAS-RTqPCR assay compared with the reference assay. In addition, our MAS-RTqPCR assay detected three patients with non-Aspergillus fumigatus infections.
CONCLUSIONS: Overall, this study demonstrates that our MAS-RTqPCR assay is a promising diagnostic for invasive aspergillosis and monitoring PCR-positive patients.
METHODS: We therefore designed, optimized, and validated a new type of real-time PCR assay using a diagnostic case-control study approach. This assay is based on reverse transcriptase qPCR methodology and multi-Aspergillus section-specific primers (multi Aspergillus species reverse transcriptase qPCR [MAS-RTqPCR]). This assay detects whole nucleic acids from species belonging to six Aspergillus sections (Fumigati, Flavi, Nigri, Terrei, Nidulantes, and Usti).
RESULTS: The limit of detection of this assay was five copies per reaction, and the analytical specificity was 100% based on the screening of >90 fungal species. We used three groups of patients to validate the assay, testing 120 patients and 223 plasma samples. The clinical sensitivity was 0.91 (95% CI, 0.71-0.98) and clinical specificity was 1.00 (95% CI, 0.93-1.00). Follow-up of positive patients revealed superiority of the MAS-RTqPCR assay compared with the reference assay. In addition, our MAS-RTqPCR assay detected three patients with non-Aspergillus fumigatus infections.
CONCLUSIONS: Overall, this study demonstrates that our MAS-RTqPCR assay is a promising diagnostic for invasive aspergillosis and monitoring PCR-positive patients.